Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6154-6157

  Bruce, R Douglas ^a   Winkle, P ^b   Custodio, J M ^c   Wei, X ^c   Rhee, M S ^c   Kearney, B P ^c   Ramanathan, S ^c   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Anaheim Clinical Trials   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBICISTAT; ELVITEGRAVIR; METHADONE; OPIATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; NARCOTIC AGENT; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; SEROLOGY; STEADY STATE; BLOOD; DRUG INTERACTION; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CARBAMATES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; QUINOLONES; THIAZOLES;

EID: 84887428402     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01229-13     Document Type: Article

References (30)

1. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R, BHIVES Collaborative. 2011. HIV treatment outcomes among HIV-infected, opioiddependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J. Acquir. Immune Defic. Syndr. 56(Suppl 1):S22-S32.
2. Bruce RD. 2010. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int. J. Drug Policy 21:122-124.
3. Kerr T, Wodak A, Elliott R, Montaner JS, Wood E. 2004. Opioid substitution and HIV/AIDS treatment and prevention. Lancet 364:1918- 1919.
4. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. 2006. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin. Infect. Dis. 43(Suppl 4):S178-S183.
5. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. 2006. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr. 41:563-572.
6. Spire B, Lucas GM, Carrieri MP. 2007. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int. J. Drug Policy 18:262-270.
7. Lucas GM, Gebo KA, Chaisson RE, Moore RD. 2002. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16:767-774.
8. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. 2007. Adherence, drug use, and treatment failure in a methadone-clinicbased program of directly administered antiretroviral therapy. AIDS Patient Care STDS 21:564-574.
9. Dole VP, Nyswander M. 1965. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 193:646-650.
10. Scott CC, Robbins EB, Chen KK. 1948. Pharmacologic comparison of the optical isomers of methadone. J. Pharmacol. Exp. Ther. 93:282-286.
11. Wang JS, DeVane CL. 2003. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos 31:742-747.
12. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai- Savary L, Golay KP, Kosel M, Baumann P, Eap CB. 2002. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J. Clin. Psychopharmacol. 22:211-215.
13. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF. 1996. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9:365-373.
14. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. 2008. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363-374.
15. Chang Y, Fang WB, Lin SN, Moody DE. 2011. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin. Pharmacol. Toxicol. 108: 55-62.
16. Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. 2012. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology 116: 432-447.
17. Kharasch ED, Whittington D, Ensign D, Hoffer C, Bedynek PS, Campbell S, Stubbert K, Crafford A, London A, Kim T. 2012. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 91:673-684.
18. Eap CB, Buclin T, Baumann P. 2002. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41:1153-1193.
19. Gonzalez F, Coughtrie M, Tukey RH. 2011. Drug metabolism, p 123- 144. In Goodman LS, Brunton LL, Chabner B, Knollmann BC (ed), Goodman & Gilman's the pharmacological basis of therapeutics, 12th ed. McGraw-Hill, New York, NY.
20. Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B, Borg L, Ott J, Adelson M, Kreek MJ. 2008. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 17:2219-2227.
21. Ramanathan S, Mathias AA, German P, Kearney BP. 2011. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin. Pharmacokinet. 50:229-244.
22. Gilead Sciences. 2012. Product Information. Stribild, elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate. Gilead Sciences, Foster City, CA.
23. Mathias AA, German P, Murray BP, Wei L, Jain A, West S, Warren D, Hui J, Kearney BP. 2010. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther. 87:322-329.
24. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. 1987. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 13:293-308.
25. Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. 2005. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 19:1635-1641.
26. Ramanathan S, Wang H, Stondell T, Cheng A, Kearney BP. 2012. Pharmacokinetics and drug interaction profile of cobicistat boostedelvitegravir with atazanavir, rosuvastatin, or rifabutin, vol O-03. 13th Int. Workshop Clin. Pharmacol. HIV Ther. Barcelona, Spain.
27. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. 2003. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. 37:476-482.
28. Gerber JG, Rhodes RJ, Gal J. 2004. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16: 36-44.
29. Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. 2013. Areview of pharmacological interactions between HIV or hepatitisCvirus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev. Clin. Pharmacol. 6:249-269.
30. Fung HB, Stone EA, Piacenti FJ. 2002. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin. Ther. 24:1515-1548.